Market Prognosis

A concise summary of the major macro events of the past 24 hours, and selected UK company-specific news.

<< Back to Market PROGnosis archive

April 11, 2023

SPAC swoop

Macro & Overnight

The extended weekend media talked about the perilous state of the US commercial real estate sector and the global threat to the US dollar trading system as the next risk vectors for the US and world financial system.

However, the dollar has strengthened, yields are stable, and the gold price has eased below $2000. Meanwhile, Bitcoin, sometimes called digital gold, has increased through the $30000 level (up 80% YTD), coinciding with suggestions that Coinbase is looking to adopt the Bitcoin Lightning Network.

US inflation data is released tomorrow. Consensus estimates are for the annual rate to decline from 6% to 5.2%.


UK Company News

Biopharma Credit, the specialist life sciences debt provider, has agreed a senior secured loan for ImmunoGen. BioPharma-V will invest up to US$62.5m in parallel with the Company. The loan matures in 2028 and will bear interest at 3-month SOFR plus 8.00%. ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients by generating targeted therapies with enhanced anti-tumour activity and favourable tolerability profiles.

Biopharma is a highly specialist lender with deep domain knowledge of biotech products it lends against future revenue streams.  

Spectral MD, a small US-based wound care company with novel technology, is being acquired by a US-listed SPAC at some 4x its recent market valuation. 

Spectral MD has interesting technology but was always subscale to find capital away from its home market efficiently. However, today’s news will undoubtedly be headlined as another blow to the UK listing regime for technology companies.  

Sustainable fund manager Impax Asset Management announced an increase in AUM of 5.7%. It cited that policy moves such as the Inflation Reduction Act in the US and similar measures in Europe and Asia have already attracted capital flows into many areas of the economy in which Impax invests. 

Fund administrator JTC had FY results with revenue up 35.6%, driven by record net organic growth of 12.0%. It also recorded new business wins and solid cash conversion. It says that momentum continued in the new year. It has a healthy M&A pipeline and is retaining medium-term guidance metrics.  


This communication is provided for information purposes only, and is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Investors should seek advice from an Independent Financial Adviser or regulated stockbroker before making any investment decisions. Progressive Equity Research Ltd (“PERL”) does not make investment recommendations.

Opinions contained in this communication represent those of PERL and/or our affiliates at the time of publication and PERL does not undertake to provide updates to any opinions or views expressed. PERL does not hold any positions in the securities mentioned in this communication, however, PERL’s directors, officers, employees, contractors and affiliates may hold a position,  and/or may perform services or solicit business from, any of the companies or related securities mentioned.

Any prices quoted in our research are as at the previous day’s close.